Urtica dioica Agglutinin Prevents Rabies Virus Infection in a Muscle Explant Model

Bibliographic Details
Title: Urtica dioica Agglutinin Prevents Rabies Virus Infection in a Muscle Explant Model
Authors: Xinyu Wang, Lisanne Terrie, Guanghui Wu, Els J. M. Van Damme, Lieven Thorrez, Anthony R. Fooks, Ashley C. Banyard, Dirk Jochmans, Johan Neyts
Source: Pharmaceutics, Vol 15, Iss 5, p 1353 (2023)
Publisher Information: MDPI AG, 2023.
Publication Year: 2023
Collection: LCC:Pharmacy and materia medica
Subject Terms: antiviral, rabies virus, lectin, muscle explant, Pharmacy and materia medica, RS1-441
More Details: Infection with the rabies virus (RABV) results in a 100% lethal neurological disease once symptoms develop. Post-exposure prophylaxis (PEP) consists of a combination of vaccination and anti-rabies immunoglobulins (RIGs); it is 100% effective if administered early after exposure. Because of its limited availability, alternatives for RIGs are needed. To that end, we evaluated a panel of 33 different lectins for their effect on RABV infection in cell culture. Several lectins, with either mannose or GlcNAc specificity, elicited anti-RABV activity, of which the GlcNAc-specific Urtica dioica agglutinin (UDA) was selected for further studies. UDA was found to prevent the entry of the virus into the host cell. To further assess the potential of UDA, a physiologically relevant RABV infection muscle explant model was developed. Strips of dissected swine skeletal muscle that were kept in a culture medium could be productively infected with the RABV. When the infection of the muscle strips was carried out in the presence of UDA, RABV replication was completely prevented. Thus, we developed a physiologically relevant RABV muscle infection model. UDA (i) may serve as a reference for further studies and (ii) holds promise as a cheap and simple-to-produce alternative for RIGs in PEP.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1999-4923
Relation: https://www.mdpi.com/1999-4923/15/5/1353; https://doaj.org/toc/1999-4923
DOI: 10.3390/pharmaceutics15051353
Access URL: https://doaj.org/article/d834598d5687496d99017d5dbc7d099f
Accession Number: edsdoj.834598d5687496d99017d5dbc7d099f
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:19994923
DOI:10.3390/pharmaceutics15051353
Published in:Pharmaceutics
Language:English